iBio IBIO 深 沪
等待开盘 08-23 09:30:00 美东时间
0.791
+0.015
+1.89%
华盛通- 最 高0.8189
- 今 开0.744
- 成交量 41.26万股
- 最 低 0.744
- 昨 收 0.7763
- 总市值 1306.68万
- 52周最高 6.8908
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.5562
- 委 比 98.57%
- 总股本 1651.93万
- 历史最高 17400.00
- 量 比 0.33
- 振 幅 9.65%
- 历史最低 0.5562
- 每 手 1
- 风险率 1.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多iBio prices $50M public offering
iBio (NASDAQ:IBIO) announced a $50M underwritten public offering. The offering includes 71.54M pre-funded warrants and Series G and H warrants to purchase a total of 71.54M shares. Each unit (1 pre-fu...
08-19 20:21
iBio Announces Pricing of $50 Million Public Offering
iBio, Inc. announced the pricing of an underwritten offering, including pre-funded warrants and Series G and H warrants, with a combined public price of $0.699 per unit. The offering is expected to close on August 22, 2025, and is projected to raise approximately $50 million before costs. Proceeds will be used to advance preclinical programs, including IBIO-610 and IBIO-600, and for general corporate purposes. Leerink Partners led the offering, w...
08-19 12:01
iBio Highlights Advancements in Obesity Pipeline
Ibio ( ($IBIO) ) has provided an update. On August 18, 2025, iBio updated its c...
08-19 04:50
iBio drops on proposed public offering
iBio (NASDAQ:IBIO) said on Monday that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of iBio’s common stock, and (ii) accompanying Series G warrants an...
08-19 04:12
iBio Announces Proposed Public Offering
iBio, Inc. (Nasdaq: IBIO), an AI-driven biotech company, has announced the commencement of an underwritten public offering of pre-funded warrants and accompanying Series G and Series H warrants. The proceeds will be used to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and other pipeline assets. Leerink Partners is the lead bookrunning manager, with LifeSci Capital and Oppenheimer acting as bookrunning manager...
08-18 20:01
Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue
Impact Biomedical Inc. (IBO) announces the issuance of U.S. Patent No. 12,357,584 B2 for a method and composition using plant-derived functional fragrances to control infectious diseases. This invention, developed under IBO’s 3F™ technology platform, demonstrates potential as an antibacterial and antiviral agent, with applications against pathogens like E. coli, MRSA, influenza, and more. The patent expands IBO’s portfolio and underscores its com...
08-18 12:30
Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies
Intelligent Bio Solutions Inc. reported a 16% revenue growth in Q4 2025, driven by increased demand for drug testing cartridges. The company advanced efforts to secure U.S. FDA 510(k) clearance for its opiate test system, aiming to expand beyond Forensic Use Only settings. Fiscal 2025 marked higher-margin cartridge sales and operational improvements, with a customer base exceeding 450 accounts across 24 countries. Expansion efforts continue in Ca...
08-15 12:30
OptiBiotix Launches SlimBiome® in Leading US Weight Loss Brand
OptiBiotix Health ( ($GB:OPTI) ) has shared an announcement. OptiBiotix Health ...
08-14 14:24
Intelligent Bio Solutions to Participate in the Sidoti Micro-Cap Virtual Conference on August 20-21, 2025
Intelligent Bio Solutions Inc. announced that its management team will participate in the Sidoti Micro-Cap Virtual Conference on August 21, 2025, at 9:15 a.m. ET. The Company, which specializes in rapid, non-invasive drug testing solutions, will discuss its Intelligent Fingerprinting Drug Screening System, designed for workplace safety. To learn more or schedule a meeting, contact Sidoti or KCSA Strategic Communications. Visit http://www.ibs.inc ...
08-12 12:30
Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum
Intelligent Bio Solutions Inc. expects a 16% sequential and year-over-year revenue growth in its fiscal fourth quarter ended June 30, 2025, driven by higher-margin cartridge sales and account growth. The company submitted an FDA 510(k) application for its opiate test system, upgraded its drug screening system for global adoption, and launched localized websites and CRM enhancements in Europe, the Middle East, and Latin America. Preliminary result...
08-07 12:30
